Friday, March 22, 8:15 AM
China-focused SciClone Pharmaceuticals (SCLN -0.9%) has appointed former Simcere Pharmaceutical Group Executive VP Hong Zhao as its CEO of operations in China. SciClone, which markets its flagship drug ZADAXIN in over 30 countries, said Mr. Zhao has a proven track record of delivering "strong top and bottom-line performance."
Comment![Healthcare, Global & FX]
Friday, February 22, 4:29 PM
SciClone Pharmaceuticals (SCLN) says it will be restating financial statements for fiscal Q1, Q2, Q3 of 2011 as well as Q2 and Q3 in 2012 to account for accounting errors within its NovaMed subsidiary in China. The restatement primarily relates to accounting errors over the timing of Pfizer product revenue recognition and the recognition of product return reserves for its Aggrastat anticoagulant drug. SCLN acquired NovaMed in April 2011. Shares -6% AH.
1 Comment[Healthcare, Earnings]
Monday, January 7, 2:52 PM
SciClone Pharmaceuticals (SCLN +0.5%) updates its 2013 outlook, now expecting an initial EPS of $0.66 - $0.72 per share on revenues of between $150M - $155M. Analysts are looking for the company to earn $0.65 on revenue of around $152M.
Friday, November 9, 2012, 6:21 AMSciClone Pharmaceuticals (SCLN): Q3 EPS of $0.20 misses by $0.01. Revenue of $40.6M (+8.8% Y/Y). (PR)
Thursday, August 9, 2012, 2:31 PM
SciClone Pharmaceuticals (SCLN +16.8%) are soaring after its Q2 bottom line topped Street estimates late yesterday. Total revenue jumped 22% Y/Y, helped by a 27% increase in sales of its drug Zadaxin, plus revenue growth from its primary care and oncology businesses in China and positive synergies from its recent takeover of NovaMed Pharmaceuticals.
Comment![Healthcare, Earnings, On the Move]
Wednesday, August 8, 2012, 4:06 PMSciClone Pharmaceuticals (SCLN): Q2 EPS of $0.20 beats by $0.02. Revenue of $40.3M (+21.8% Y/Y) in-line. Shares +0.4% AH. (PR)
Wednesday, July 11, 2012, 9:48 AM
SA author The GeoTeam argues that SciClone (SCLN) faces risks that should see it trade at $2.65-$3.80. These include: the failure of the firm's Zadaxin drug, its lead product, in multiple Phase III studies for various uses; probable price reductions in China, SciClone's main source of revenue; and an SEC investigation into bribery in the country. Shares -5.4% to $6.50.
Comment![Healthcare, On the Move]
Wednesday, May 9, 2012, 5:10 PMSciClone Pharmaceuticals (SCLN): Q1 EPS of $0.15 beats by $0.04. Revenue of $39.2M (+81% Y/Y) beats by $2M. Shares +1.7% AH. (PR)